Drug intelligence / Profile preview

SGN-102

Development stage: Unknown
Lead developer: SGN Nanopharma
Modality: Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems

Overview

SGN-102 is an investigational micellar nanoparticle (MNP) formulation of cyclosporine developed by SGN Nanopharma for the treatment of rheumatoid arthritis. Utilizing SGN's proprietary MNP platform, SGN-102 is designed to deliver cyclosporine—a cyclic peptide calcineurin inhibitor—in a multiphasic nanoparticle system. This formulation aims to enhance the bioavailability, safety, and tolerability of cyclosporine, providing sustained release and improved tissue penetration while reducing systemic side effects and irritation associated with conventional cyclosporine therapies. SGN-102 is currently in early-stage development (early human / anecdotal proof-of-concept) for rheumatoid arthritis.

Other names: MNP-Cyclosporinemicellar nanoparticle cyclosporine

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)

Beyond the preview

Go deeper on SGN-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGN-102.